Objective: This trial is conducted to investigate the benefit of trastuzumab monotherapy compared with a combination therapy of trastuzumab and chemotherapy in women over 70 years with human epidermal growth factor receptor type-2-positive primary breast cancer. Methods: Inclusion criteria are the following: histologically diagnosed as invasive breast cancer and received curative operation for primary breast cancer; Stage I, IIA, IIB or IIIA/M0; and baseline left ventricular ejection fraction is !55%. Patients are randomized to receive either trastuzumab (8 mg/kg loading dose, 6 mg/kg every 3 weeks for 1 year) plus chemotherapy selected from regimens specified on the protocol or trastuzumab monotherapy. The primary endpoint is disease-free survival. Secondary endpoints are overall survival, relapsefree survival, safety, health-related quality of life, comprehensive geriatric assessment and cost effectiveness. Results: Patients recruitment has been commenced in October 2009. Enrollment of 300 patients is planned during the 4-year recruitment period. Conclusions: We hereby report the study concept.
INTRODUCTION
Trastuzumab with chemotherapy is the standard treatment as an adjuvant systemic therapy for human epidermal growth factor receptor type-2 (HER2)-positive primary breast cancer (1 -4) . Overexpression of HER2 has also been associated with potentially more aggressive tumors; therefore, trastuzumab is a key drug in the treatment of HER2-positive primary cancer. However, monotherapy of trastuzumab as an adjuvant treatment without concurrent or preceding chemotherapy is not conducted in clinical practice since its benefit has not been investigated as well as elderly patients (5) . It has clinical significance to demonstrate the benefit of trastuzumab monotherapy without toxicity induced by chemotherapy, especially in elderly patients. Chemotherapy is not always a standard therapy in elderly patients based on the analysis of Early Breast Cancer Trialists' Collaborative Group (EBCTCG) because of limited data (6) . Careful monitoring is necessary for elderly patients due to toxicity, cardiac toxicity associated with anthracycline-containing chemotherapy (7, 8) , increasing in acute myeloid leukemia (AML) after adjuvant chemotherapy (9) .
This trial is conducted to investigate the clinical positioning between trastuzumab monotherapy (H group) and a combination therapy of trastuzumab and chemotherapy (H þ CT group) based on a randomized controlled trial in women over 70 years with HER2-positive primary breast cancer.
DIGEST OF THE STUDY PROTOCOL

PURPOSE
This study is conducted to investigate the clinical positioning between trastuzumab (Herceptin) monotherapy (H group) and a combination therapy of trastuzumab and chemotherapy (H þ CT group) based on a randomized controlled trial in women over 70 years with HER2-positive primary breast cancer (Fig. 1) 
PATIENT ASSIGNMENT
The CSPOR Data Center will confirm patient eligibility, and treatment will be automatically assigned according to the assignment adjustment factors for eligible patients. The following five variables will be used as assignment adjustment factors: age (70 -75/76 -80), PS (0/1), hormone sensitivity, lymph node metastasis and hospital.
TREATMENT
COMBINATION THERAPY OF TRASTUZUMAB AND CHEMOTHERAPY ARM
The loading administration dose of trastuzumab is 8 mg/kg of body weight, and the maintenance dose is 6 mg/kg every 3 weeks for 1 year. Chemotherapy is selected from regimens specified on the protocol based on the decision of a physician or a patient. Administration of trastuzumab initiates after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF.
If the hormone receptor is positive, hormone therapy is indicated. In the case of after breast conservative operation, irradiation for breast is indicated after chemotherapy.
TRASTUZUMAB MONOTHERAPY ARM
The loading dose of trastuzumab is 8 mg/kg of body weight, and the maintenance dose is 6 mg/kg every 3 weeks for 1 year.
If hormone receptor is positive, hormone therapy is indicated. In case of after breast conservative operation, irradiation for breast is indicated after surgery or concurrent with trastuzumab. 
STRATIFICATION FACTORS
MAIN ANALYSIS AND ASSESSMENT CRITERIA
To evaluate the clinical position of each treatment, the estimated hazard ratio is compared with a threshold hazard ratio of 1.69. Concretely, the threshold will be used to determine whether the H þ CT group is equivalent (not inferior) to the H group with regard to DFS. As an aid to interpret the trial result, we will estimate the three posterior probabilities between and outside the following two thresholds: 'the upper threshold of hazard ratio (1.69) to select the combination therapy of trastuzumab and chemotherapy' and 'the lower threshold (1.22) to select the monotherapy of trastuzumab', using the posterior distribution of log hazard ratio based on a non-informative prior.
SAMPLE SIZE AND FOLLOW-UP PERIOD
The primary endpoint will require 120 events in total, given a power of 80% and a threshold hazard ratio of 1.69. Giving that the 3-year DFS probability in the study population is 68% and assuming that the survival time follows the exponential distribution, a total of 260 patients will be necessary for 3 years of follow-up after 4 years of registration to assess the 120 events. Therefore, the target number of registration was determined to be 300 since exponential distribution of survival might not be shown because of the elderly population and dropout patients were expected.
This study has been started from October 2009 and completion is scheduled in October 2016 with a registration period for 4 years and a follow-up period for 3 years.
